STOCK TITAN

Bio-Techne Corp - TECH STOCK NEWS

Welcome to our dedicated news page for Bio-Techne (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bio-Techne's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bio-Techne's position in the market.

Rhea-AI Summary
Bio-Techne Corporation launches Maurice Chromeleon Driver Kit for its Maurice instrument, enabling control with Chromeleon Chromatography Data System. Integration enhances efficiency and productivity in the laboratory.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
none
-
Rhea-AI Summary
Bio-Techne issues 2023 Corporate Sustainability Report, emphasizing progress in ESG initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
none
-
Rhea-AI Summary
Bio-Techne and Cizzle Biotechnology announce progress in evaluating monoclonal antibodies for cancer biomarker detection
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
Rhea-AI Summary
Bio-Techne to present at investor healthcare conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
conferences
-
Rhea-AI Summary
Bio-Techne Corporation to host Investor Day on September 8, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
none
-
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) announced that its CFO will present at the UBS MedTech, Tools and Genomics Summit 2023 on August 17, 2023. Bio-Techne is a leading developer and manufacturer of high-quality purified proteins and reagent solutions. In fiscal 2023, the company generated approximately $1.1 billion in net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
conferences
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) ends collaboration with Akoya Biosciences to co-develop an automated RNAscope™ workflow for use with the PhenoCycler®-Fusion System. The company remains focused on providing value to the spatial biology community, expanding the capabilities of RNAscope technology and accelerating the development of a fully automated spatial multiomics workflow on the Lunaphore COMET™ system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
-
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) reported 5% organic revenue growth in Q4 FY2023, reaching $301.3 million. GAAP EPS increased to $0.47, and adjusted EPS to $0.55. The acquisition of Lunaphore strengthened the spatial biology franchise. Full year revenue increased 3% to $1.1 billion, with adjusted EPS at $1.99.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
-
News
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) announces a $0.08 per share dividend for Q2 2023, payable on September 1, 2023, to shareholders of record on August 18, 2023. The company is a global life sciences provider with approximately $1.1 billion in net sales in fiscal 2023, offering innovative tools and bioactive reagents for research and clinical diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
dividends
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) will host a conference call and webcast on August 8, 2023, at 8:00 a.m. CDT to review fourth quarter and fiscal 2023 financial results. The company, a leading developer and manufacturer of high-quality purified proteins and reagent solutions, expects to discuss its $1.1 billion net sales in fiscal 2022 and its diverse product portfolio, including cytokines, growth factors, antibodies, immunoassays, small molecule compounds, and genomic tools. The webcast will be available for replay until September 8, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
conferences earnings
Bio-Techne Corp

Nasdaq:TECH

TECH Rankings

TECH Stock Data

10.49B
155.39M
0.97%
100.54%
3.39%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Minneapolis

About TECH

bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.